SS-31 Peptide: Mitochondrial-Targeted Antioxidant Science

By Sam Smith

Conventional antioxidants — vitamin C, vitamin E, CoQ10 — distribute throughout the cell and mop up reactive oxygen species wherever they encounter them. SS-31 doesn't work that way. The tetrapeptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2), designed by Hazel Szeto and Peter Schiller at Weill Cornell, concentrates in the inner mitochondrial membrane through electrostatic interactions with cardiolipin — the phospholipid uniquely enriched in that membrane and essential for the structural integrity of the cristae where the electron transport chain sits. By targeting the exact location where mitochondrial ROS is generated, SS-31 can reduce oxidative stress at its source rather than trying to catch it downstream.

The cardiolipin connection is what makes SS-31 mechanistically distinctive. Cardiolipin does more than provide a structural scaffold — it directly supports the function of Complex I, Complex III, and cytochrome c oxidase (Complex IV). In aging and mitochondrial disease, cardiolipin oxidizes and the cristae structure collapses, reducing electron transport efficiency and increasing electron leak (which generates more ROS in a self-amplifying cycle). SS-31 appears to bind cardiolipin, protect it from oxidation, and preserve cristae architecture — with downstream effects on membrane potential, ATP synthesis, and the ROS-generating electron leak. The Phase 2 TAZPOWER trial in Barth syndrome patients (published in JCI Insight, 2020) showed that SS-31 improved exercise capacity in a disease defined by cardiolipin remodeling dysfunction — a meaningful proof-of-mechanism result in humans.

This guide covers SS-31's mechanism at the inner mitochondrial membrane, what the rodent and human data show on mitochondrial function, oxidative stress, cardiac protection, and clinical endpoints, comparisons with other mitochondrial-targeted antioxidant strategies, and what researchers need to know about sourcing and study design.

What does SS-31 do to mitochondrial biology?

SS-31 is a mitochondria-targeted peptide that accumulates in the inner mitochondrial membrane and binds cardiolipin, the phospholipid that organises the cristae and stabilises the electron transport chain. By holding cardiolipin in its tetra-acylated form, the peptide preserves cristae curvature, supports complex IV (cytochrome c oxidase) activity, and prevents the cardiolipin peroxidation that triggers mitochondrial permeability transition and apoptosis. According to a 2025 PubMed-indexed mitochondrial biology review, mitochondria serve an essential metabolic and energetic role in cellular activity, which is why a compound that stabilises mitochondrial membrane potential and reduces mitochondrial ROS has potential effects across tissue types.

In rodent and human models, SS-31 treatment increases mitochondrial ATP synthesis under stress, reduces reactive oxygen species emission from the electron transport chain, and restores mitochondrial respiration in aged cells. Published research shows that the synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function across a wide range of disease and aging models, an effect attributed to its cardiolipin-binding selectivity.

How does SS-31 work as a mitochondria-targeted antioxidant?

The mechanism is structural, not chemical. According to the original PubMed-indexed cardiolipin paper from the Szeto group, SS-31 binds with high affinity to cardiolipin, sequestering it in the bent shape that supports cristae curvature. The peptide does not scavenge ROS directly; instead, it preserves the membrane architecture that prevents ROS generation in the first place. This is the defining distinction between SS-31 and bulk antioxidants like vitamin E, NAC, or coenzyme Q10.

Published research shows that SS-31 modulated the surface electrostatics of both model and mitochondrial membranes, increasing the negative surface potential that drives ATP synthase efficiency. The protective effect on mitochondrial membrane potential, the inhibition of mitochondrial permeability transition pore opening, and the ability to ameliorate the cardiolipin peroxidation that follows ischemia-reperfusion injury all stem from this single cardiolipin-binding mechanism.

Effects of SS-31 in disease and aging models

The protective effects of SS-31 have been characterised across cardiovascular, renal, neurological, ophthalmic, and skeletal muscle models. SS-31 treatment in rodent ischemia-reperfusion models reduces infarct size, reduces oxidative damage to cardiolipin, and restores mitochondrial respiration in surviving tissue. In aged-mouse skeletal muscle, the peptide ameliorates age-related decline in mitochondrial respiration and reduces mitochondrial ROS leak. In diabetic nephropathy models, SS-31 reduces tubular cell apoptosis and ameliorates the cardiolipin-mediated oxidative damage that drives kidney decline. In retinal models, the peptide ameliorates the photoreceptor mitochondrial dysfunction that drives age-related macular degeneration.

According to a 2025 PubMed-indexed clinical review, elamipretide is a potential first-in-class therapeutic that targets the inner mitochondrial membrane, with phase 2/3 data in Barth syndrome (a cardiolipin-remodelling genetic disease), primary mitochondrial myopathy, and dry age-related macular degeneration. The FDA accepted a new drug application for elamipretide in Barth syndrome in 2024, the first regulatory milestone for any mitochondria-targeted peptide.

Can SS-31 reverse aging?

“Reverse aging” overstates the published data. What SS-31 does in aged-rodent models is restore mitochondrial respiration and mitochondrial ATP output toward young-adult levels in specific tissues (skeletal muscle, heart, kidney, retina) during the treatment window. The benefit is dependent on continued dosing; mitochondrial parameters return toward baseline when treatment stops. The compound addresses one specific aging hallmark (mitochondrial dysfunction) and does not reverse genomic, telomeric, or epigenetic aging markers. As an intervention against the mitochondrial component of aging, the evidence is real; as an “anti-aging cure”, the framing is wrong.

What is the best antioxidant for mitochondria?

“Best” depends on the question. For cardiolipin-protective and cristae-stabilising effects, the mitochondria-targeted antioxidant SS-31 is the most-developed compound. For lipid-peroxidation prevention in membranes more broadly, MitoQ (mitoquinone, a triphenylphosphonium-conjugated coenzyme Q10 analogue) is the most-studied alternative. For NAD+ pool restoration, nicotinamide riboside and NMN are the leading interventions. SS-31 is the only mitochondrial antioxidant peptide in clinical trials at the time of writing; the small-molecule competitors are either dietary supplements or earlier-stage clinical candidates.

How does SS-31 compare to MitoQ and other mitochondria-targeted antioxidants?

MitoQ and SS-31 share a target (the inner mitochondrial membrane) but differ in mechanism. MitoQ accumulates electrochemically via the triphenylphosphonium cation and acts as a chain-breaking antioxidant, scavenging lipid peroxyl radicals. SS-31 binds cardiolipin and stabilises membrane architecture. The MitoQ mechanism is concentration-dependent and can become pro-oxidant at high doses; the SS-31 mechanism is structural and does not have that inversion. Both compounds reduce mitochondrial ROS in cell and animal models; only SS-31 has restore mitochondrial function data in late-phase human trials. The two are not interchangeable, and in research protocols that compare them, head-to-head dose-matching is non-trivial.

Clinical trial status

Elamipretide (the clinical name for SS-31) has been studied in phase 2 trials in primary mitochondrial myopathy, age-related macular degeneration, heart failure with preserved ejection fraction, and renal disease. The most advanced indication is Barth syndrome, a rare cardiolipin-remodelling genetic condition; Stealth BioTherapeutics submitted an NDA to the FDA in 2024 based on TAZPOWER and SPIBA-201 data, and the compound received Priority Review designation. As of 2026, no FDA approval is finalised, but the regulatory pathway is the most advanced for any mitochondria-targeted antioxidant.

Safety and side effects

SS-31 treatment in published trials has been well-tolerated. The most common adverse events are injection-site reactions (subcutaneous formulation), mild headache, and transient nausea. No hepatotoxicity, cardiac signal, or off-target receptor binding has been documented at clinical doses. In rodent chronic-dose studies, no dose-limiting toxicity has been identified at standard preclinical ranges. The long-term safety dataset is still being built, but the compound has an unusually clean profile for a peptide therapeutic.

Dosing and routes of administration

Clinical SS-31 trials have used subcutaneous injection at doses ranging from 4 mg to 60 mg per day depending on indication. Research protocols add intravenous administration in some acute-injury models. The peptide is not orally bioavailable; the inner mitochondrial membrane targeting depends on the peptide reaching circulation intact. The compound is supplied as a lyophilised powder for reconstitution in bacteriostatic water, with mass-spectrometry verification against the expected ~640 Da tetrapeptide mass.

Is SS-31 peptide legal?

SS-31 (elamipretide) is not yet approved by Health Canada or the FDA as a finished pharmaceutical. The NDA for Barth syndrome is pending. Research-grade SS-31 is legal in Canada and the United States as a research chemical sold under research-use-only labelling, distinct from any future finished pharmaceutical. The peptide is not on the World Anti-Doping Agency prohibited list as of 2026.

Purity and sourcing for researchers

Reproducible peptide research depends on the integrity of the input material. Four checks at the supplier level matter:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace included
• Mass spectrometry verification against the expected ~640 Da tetrapeptide mass
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies SS-31 (elamipretide) at 10 mg per vial with third-party COA and HPLC purity confirmation. View the SS-31 10mg product page.

SS-31 mitochondrial antioxidant questions

What does SS-31 do to your body?

SS-31 enters cells, accumulates in the inner mitochondrial membrane, and binds cardiolipin. The downstream effect is stabilised mitochondrial membrane potential, reduced mitochondrial ROS, preserved cristae architecture, and restored mitochondrial respiration in cells under oxidative stress or mitochondrial dysfunction.

Can SS-31 reverse aging?

SS-31 reverses the mitochondrial dysfunction component of aging in rodent models during the treatment window; benefits return toward baseline when treatment stops. It does not reverse genomic, telomeric, or epigenetic aging markers. The “anti-aging cure” framing overstates the published data.

What is the best antioxidant for mitochondria?

For cardiolipin-protective effects with the most clinical data, the mitochondrial antioxidant SS-31 leads. MitoQ is the most-developed small-molecule alternative. NMN and NR address NAD+ pools, which is a complementary intervention rather than a direct mitochondria-targeted antioxidant.

Is SS-31 peptide legal?

SS-31 is not yet FDA or Health Canada-approved as a finished pharmaceutical (NDA pending for Barth syndrome). Research-grade material is legal in Canada and the United States under research-use-only labelling. Not on the WADA prohibited list.

How does SS-31 work as a mitochondrial antioxidant?

It binds cardiolipin in the inner mitochondrial membrane and stabilises cristae architecture, which preserves mitochondrial membrane potential, reduces mitochondrial ROS at the source, and inhibits mitochondrial permeability transition. It is a structural antioxidant rather than a radical scavenger.

Key data point: Szeto et al. (2014, JASN) demonstrated that a single SS-31 IV infusion in mice with established ischaemia-reperfusion kidney injury normalised mitochondrial respiration within 24 hours and reduced serum creatinine by 60% at 48 hours — with effects attributed specifically to cardiolipin binding and cristae architecture restoration, not anti-inflammatory pathways.

Summary

SS-31 is the most-developed mitochondria-targeted peptide in clinical research, acting through a cardiolipin-binding mechanism that stabilises the inner mitochondrial membrane rather than directly scavenging radicals. The protective effects of SS-31 span cardiovascular, renal, neurological, ophthalmic, and skeletal muscle disease models, and the compound has phase 2/3 clinical data in Barth syndrome, primary mitochondrial myopathy, and macular degeneration. It is not approved as a finished pharmaceutical; research-grade material is legal in Canada and the United States under research-use-only labelling. For researchers studying mitochondrial dysfunction, oxidative damage, or aging-related mitochondrial decline, SS-31 is the most-validated chemical probe in its class.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.